F S&P 500
5,522.25 +5.25 (+0.10%) F Dow Jones
39,895.00 +51.00 (+0.13%) F Nasdaq
19,792.00 +41.25 (+0.21%) E-mini Russell 2000 Index Futur
2,057.50 +4.70 (+0.23%) Petróleo
81.66 +0.03 (+0.04%) Oro
2,336.20 -8.20 (-0.35%)
Ocuphire Pharma, Inc. (OCUP)
Fuera de horario:
Ocuphire Pharma, Inc.
37000 Grand River Avenue
Suite 120
Farmington Hills, MI 48335
United States
(248) 957-9024
https://www.ocuphire.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 14
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. George Magrath M.B.A., M.D., M.S. | CEO & Director | 625.07k | N/D | 1984 |
| Mr. Bernhard Hoffmann M.B.A. | Senior Vice President of Corporate Development & Secretary | 434.1k | N/D | 1956 |
| Dr. Jay S. Pepose M.D., Ph.D. | Chief Medical Advisor & Director | 392k | N/D | 1955 |
| Ms. Amy Zaremba Rabourn C.P.A., MAcc | Senior Vice President of Finance | 434.1k | N/D | 1981 |
| Mr. Nirav Suresh Jhaveri C.F.A. | Chief Financial Officer | N/D | N/D | 1978 |
| Mr. Joseph K. Schachle MBA | Chief Operating Officer | N/D | N/D | 1965 |
| Dr. Ashwath Jayagopal Ph.D. | Chief Scientific & Development Officer | N/D | N/D | 1982 |
| Ms. Bindu Manne | Head of Market Development & Commercialization | N/D | N/D | N/D |
| Mr. Erik Sims | Director & Corporate Controller | N/D | N/D | N/D |
Descripción
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Gestión corporativa
La calificación ISS Governance QuickScore de Ocuphire Pharma, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
